FDA staff question dosing of Sanofi combination diabetes drug
May 23, 2016 at 08:49 AM EDT
May 23 (Reuters) - A preliminary review by the U.S. Food and Drug Administration questioned whether Sanofi SA's experimental drug lixisenatide contributed any benefit to a fixed-dose combination diabetes product the company hopes to market.
